Journals / Türk Toraks Dergisi / 2010 / Cilt: 11 - Sayı: 3

Analysis of prognostic factors in stage IIIB-IV non-small cell lung cancer cases who received chemotheraphy

Kemoterapi almış olan evre IIIB-IV küçük hücreli dışı akciğer kanserli olgularda prognostik faktörlerin incelenmesi

Pages
93–97
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Good ECOG performance status, normal LDH levels and <65 age play important roles in longer survival with advanced non-small cell lung cancer cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Prognostic factors which influence survival which are definitive in the advanced stage of lung cancer cases are described.
📊
Key Findings & Data:Material and Method: In this study, 193 stage IIIB-IV non-small cell lung cancer (NSCLC) outpatients who were followed up in our hospital's oncology department between January 2000 and September 2007 were retrospectively analysed.
💡
Conclusion & Impact:Conclusion: Good ECOG performance status, normal LDH levels and <65 age play important roles in longer survival with advanced non-small cell lung cancer cases.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Prognostic factors which influence survival which are definitive in the advanced stage of lung cancer cases are described. Material and Method: In this study, 193 stage IIIB-IV non-small cell lung cancer (NSCLC) outpatients who were followed up in our hospital's oncology department between January 2000 and September 2007 were retrospectively analysed. The effects of demographic clinical and laboratory findings on survival were investigated. Results: Of the cases, 170 (88.02%) were men, 23(11.92%) were women and mean age was 57.44±9.42 years. Analysis by the Kaplan-Meier method revealed that mean survival was 13.8±10.8 months. A ECOG performance status of (0), younger than 65 age, no comorbid disease and normal LDH levels were found to be significantly important factors for long term survival (p=0.01, 0.003, 0.04, 0.003). Among metastases, bone metastasis was found to be a poor prognostic factor (p=0.01). However, anemia, leucocytosis, smoking status, weight loss and pleural effusion were not prognostic factors for survival. A multivariate analysis by Cox regression method revealed that normal LDH levels (p=0.01), <65 age (p=0.008), zero ECOG performance status (p=0.009) were independent prognostic factors in stage IIIB-IV lung cancer cases. Conclusion: Good ECOG performance status, normal LDH levels and <65 age play important roles in longer survival with advanced non-small cell lung cancer cases.

Özet

Amaç: İleri evre akciğer kanserli olgularda yaşam süresini etkileyen prognostik faktörler tam olarak tanımlanmamıştır. Gereç ve Yöntem: Ocak 2000-Eylül 2007 tarihleri arasında hastanemiz onkoloji kliniğinde ayaktan takip edilen evre IIIB, IV küçük hücreli dışı akciğer kanserli (KHDAK) 193 olgu retrospektif olarak incelendi. Olguların tedavi öncesi demografik, klinik ve laboratuvar verilerinin sağkalım üzerine etkileri araştırıldı. Bulgular: Olguların 170'i (%88.08) erkek ve 23'ü (%11.92) kadın olup ortalama yaşı 57.44±9.42 ve Kaplan Meier analizinde ortalama yaşam süresi 13.8±10.8 ay idi. Performans statusunun (ECOG) sıfır olması, altmış beş yaştan genç olmak, komorbit hastalığın olmaması, LDH'nın normal olması uzun süreli yaşam süresi ile ilişkili önemli faktörler olarak bulunmasına karşın (p=0.01, 0.003, 0.04, 0.003) anemi, lökösitoz, sigara içimi, kilo kaybı ve plevral sıvı varlığının sağ-kalım üzerine etkisi yoktu. Metastazlar arasında ise kemik metastazı kötü prognostik faktör olarak bulundu (p=0.01). Cox regresyon yöntemi kullanılarak yapılan çok değişkenli analizde ise, 65 yaşından genç olmak (p=0.008), LDH seviyesinin normal olması (p=0.01) ve ECOG performans statusunun 0 olması (p=0.009) evre IIIB, IV KHDAK olgularında bağımsız prognostik faktörlerdi. Sonuç: İyi ECOG performans statusu, 65 yaştan genç olmak ve normal LDH düzeyi ileri evre küçük hücreli dışı akciğer kanserli olguların uzun yaşam süresinde önemli rol oynar.

🔖

Cite This Article

ARINÇ, S., ERDAl, N., ECE, F., HATABAY, N., ORUÇ, Ö., HAZAR, A. (2010). Analysis of prognostic factors in stage IIIB-IV non-small cell lung cancer cases who received chemotheraphy. Türk Toraks Dergisi, Cilt: 11 - Sayı: 3, 93–97. https://ajindex.com/articles/329547

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Okamoto T, Maruyama R, Shoji F, et al. Long-term survivors in stage IV non small cell lung cancer. Lung Cancer 2005;47:85-91
  2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7
  3. The treatment of advanced non-small cell lung cancer. Spiro SG, Silvestri GA. Curr Opin Med 2005;11:287-91
  4. Wigren T. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 1997;44:9-15
  5. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55
  6. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003;123:226S-243S
  7. Sugiura S, Ando Y, Minami H, et al. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997;3:47-50
  8. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-26
  9. Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006;107:781-92
  10. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995;13:1221-30
  11. Songür N, Kuru B, Ok U. İleri evre küçük hücreli olmayan akciğer kanserlerinde sağkalımı etkileyen prognostik faktörler. Toraks Dergisi 2005;6:91-7
  12. Tsao AS, Liu D, Lee JJ, et al. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006;106:2428-36
  13. Roland M, Rudd RM. Genetics and pulmonary medicine
  14. Somatic mutations in the development of lung cancer. Thorax 1998;53:979-83
  15. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366-73
  16. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857-62
  17. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology. American Society of Clinical Onc